In this context, NMA is a useful technique to compare the direct and indirect evidence available to assess the relative safety of SGAs in the treatment of pediatric patients diagnosed with schizophrenia and schizophrenia spectrum disorders, specifically regarding increased serum prolactin levels. This evidence concerns the gene PRL and schizophrenia.